In this study, inspired by both ferroptosis and FAK inhibitors irritating anti-tumor immune responses, a sustainable released hybrid hydrogel ED-M@CS/MC, which combined the therapeutic strategies of ferroptosis and stromal modulation for synergistic immunotherapy was designed for the combination treatment of PDAC (Scheme 1). The gene discussed is PTK2; the disease is neoplasm.